Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

41.20 -0.81 (-1.93%)

Delayed Quote Updated: 2:28 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News ↗

June 17, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

June 17, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗

June 16, 2025

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Via Stocktwits

Topics Government

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗

June 16, 2025

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Via Benzinga

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗

June 16, 2025

The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.

Via Investor's Business Daily

Topics ETFs

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

June 16, 2025

From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.

Via GlobeNewswire

3 Small-Cap Stocks Facing Headwinds

June 13, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar

June 10, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 29, 2025

New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 28, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

3 Cash-Heavy Stocks in the Doghouse

May 21, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

May 20, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

3 Dawdling Stocks with Mounting Challenges

May 15, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 Stocks Under $50 That Concern Us

May 07, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations

May 06, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the...

Via StockStory

Topics Earnings

Supernus Announces First Quarter 2025 Financial Results

May 06, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview ↗

May 05, 2025

Via Benzinga

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

May 05, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

April 29, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

3 Healthcare Stocks with Mounting Challenges

April 24, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

April 23, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 22, 2025

Uncover the potential of SUPERNUS PHARMACEUTICALS INC, an undervalued stock. NASDAQ:SUPN maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

April 10, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

April 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?

April 04, 2025

Supernus Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $31.52. However, the stock is beating the S&P 500’s 7% decline during...

Via StockStory

Topics Stocks Supply Chain

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

April 02, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.